Targeting the Human T-Cell Inducible COStimulator Molecule with a Monoclonal Antibody Prevents Graft-vs-Host Disease and Preserves Graft vs Leukemia in a Xenograft Murine Model [PDF]
Frontiers in Immunology, 2017 BackgroundGraft-vs-host disease (GVHD) is a major complication of allogenic bone marrow transplantation (BMT). Targeting costimulatory molecules with antagonist antibodies could dampen the excessive immune response that occurs, while preserving the ...
Aude Burlion +4 more
doaj +2 more sources
Body Composition Assessment Provides Prognostic Information in Patients With Cancer Affected by Chronic Graft vs. Host Disease [PDF]
Journal of Cachexia, Sarcopenia and MuscleBackground Additional tools are needed to assess mortality risk among patients with cancer. Patients with chronic graft vs. host disease (cGVHD) after allogeneic haematopoietic cell transplantation (HCT) represent a high‐risk cancer population with ...
Asmita Mishra +8 more
doaj +2 more sources
Toll-Like Receptor Stimulation by MicroRNAs in Acute Graft-vs.-Host Disease [PDF]
Frontiers in Immunology, 2018 Acute graft-vs.-host disease (aGVHD) is a frequent complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), accounting for substantial morbidity and mortality associated with this treatment modality.
Nina C. Zitzer +3 more
doaj +2 more sources
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report [PDF]
Journal of Hematology & Oncology, 2016 Background Allogeneic hematopoietic stem cell transplantation (HSCT) is potentially curative in a variety of hematological malignancies. Graft-vs.-host disease (GvHD) remains a life-threatening complication.
Enrico Maffini +10 more
doaj +2 more sources
AAV-mediated expression of HLA-G for the prevention of experimental ocular graft vs. host disease [PDF]
Molecular Therapy: Methods & Clinical Development, 2023 Ocular graft versus host disease (OGvHD) develops after allogeneic hematopoietic stem cell transplantation (HSCT) and manifests as ocular surface inflammatory disease.
Jacob P. Nilles +8 more
doaj +2 more sources
Post-Transplant Cyclophosphamide for the Prevention of Graft-vs.-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Guide to Management for the Advanced Practitioner. [PDF]
J Adv Pract Oncol, 2023 Kachur E +4 more
europepmc +3 more sources
Graft–Vs.–Host Disease After Liver Transplantation [PDF]
Hepatology, 1990 Clinically evident, generalized graft–vs.–host disease is not thought to occur as a consequence of transplantation of most solid organs. The large inoculum of donor lymphoid cells required and the inability of the recipient to destroy these passenger cells are apparently rarely produced by solid–organ transplantation. However,
G, Alexander, B, Portmann
openaire +3 more sources
Case report: Sudden onset optic neuritis shortly after SARS-CoV-2 vaccination in an allogeneic hematopoietic stem cell transplant recipient with chronic graft-vs.-host disease. [PDF]
Front Med (Lausanne), 2023 Chu C, Jiang SK, Shao YC, Yeh SP.
europepmc +3 more sources
FRI100 Lipoprotein X In Graft Vs. Host Disease Affecting Liver [PDF]
J Endocr Soc, 2023 Deepak Vedamurthy +4 more
europepmc +2 more sources
Graft-vs-Host Disease in a Liver Transplant Patient With COVID-19 Infection. [PDF]
ACG Case Rep J, 2023 Kiparizoska S, Nguyen V, Rangnekar AS.
europepmc +2 more sources